SCHEDULE 13D: Quanterix to Acquire Akoya Biosciences in All-Stock Merger Valued at 0.318 Shares Per Akoya Stock

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. in an all-stock transaction, with Akoya becoming a wholly-owned subsidiary of Quanterix.

Summary

• Quanterix Corporation signed an Agreement and Plan of Merger with Wellfleet Merger Sub, Inc. (a wholly-owned subsidiary of Quanterix) and Akoya Biosciences, Inc. on January 9, 2025.
• The merger will result in Akoya becoming a wholly-owned subsidiary of Quanterix.
• Each outstanding share of Akoya Common Stock will be converted into the right to receive 0.318 shares of Quanterix Common Stock, plus cash in lieu of fractional shares.
• Akoya Restricted Stock Units (RSUs) and stock options (Akoya Options) will be converted into Quanterix RSUs and options, respectively, adjusted by the 0.318 exchange ratio, retaining their original vesting terms.
• Concurrently with the Merger Agreement, Quanterix entered into a Voting and Support Agreement with a group of 'Supporting Stockholders' of Akoya.
• These Supporting Stockholders, including Akoya directors and executive officers, collectively owned approximately 55.9% of Akoya's outstanding common stock (27,714,011 shares) as of January 6, 2025.
• The Supporting Stockholders have agreed to vote their shares in favor of the merger and against any competing transactions, granting an irrevocable proxy to Quanterix for these matters.
• Upon consummation of the merger, Akoya Common Stock will be de-registered from the Securities Exchange Act of 1934, and Quanterix will control Akoya's board of directors and operations.

Sentiment

Score: 8

Explanation: The document announces a definitive merger agreement with significant shareholder support, indicating a high likelihood of successful completion. The terms are clearly laid out, and there are no apparent negative surprises or delays mentioned. The strategic rationale for Quanterix to acquire Akoya is implied by the nature of the transaction.

Positives

• The acquisition of Akoya Biosciences by Quanterix is expected to create a combined entity with enhanced capabilities in life sciences research and diagnostics.
• The Voting and Support Agreement, representing 55.9% of Akoya's outstanding shares, significantly increases the likelihood of the merger's approval by Akoya stockholders.
• The conversion of Akoya RSUs and Options into Quanterix equivalents ensures continuity for Akoya's equity incentive holders, aligning their interests with the combined company.

Negatives

• The document does not explicitly state any negatives, as it is a filing related to a merger agreement and voting support.

Risks

• The Akoya Voting Agreement can terminate under certain conditions, including termination of the Merger Agreement, a decrease in the Exchange Ratio without Supporting Stockholder consent, or an extension of the Termination Date without consent, which could jeopardize the merger.
• If the Akoya board of directors changes its recommendation regarding the merger, the number of shares subject to the voting obligation will be reduced to 35% of outstanding shares, potentially increasing uncertainty for the merger's approval.

Future Outlook

Upon consummation of the merger, Akoya will become a wholly-owned subsidiary of Quanterix, its common stock will be de-registered, and Quanterix will assume control of Akoya's board of directors and operations. Quanterix will file a registration statement on Form S-4 with the SEC, which will include a joint proxy statement/prospectus for the merger.

Management Comments

• Quanterix disclaims beneficial ownership of the Akoya Common Stock subject to the Voting Agreement, stating it is solely due to the agreement's operation for Rule 13d-3 purposes.

Industry Context

This merger represents a consolidation within the life sciences and diagnostics sector, where companies often seek to expand their technological capabilities and market reach through strategic acquisitions. Quanterix, known for its digital immunoassay platforms, is acquiring Akoya, which likely complements its existing offerings or expands into new diagnostic areas, aligning with a broader industry trend of integrating advanced detection technologies.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• The Voting and Support Agreement was entered into with 'Supporting Stockholders' who include directors and executive officers of Akoya, aligning their voting interests with Quanterix for the merger's approval.

Stakeholder Impact

• **Shareholders (Akoya):** Will receive Quanterix Common Stock, converting their ownership in Akoya into ownership in the combined entity. Akoya Common Stock will cease to be freely traded or listed.
• **Shareholders (Quanterix):** Will experience dilution due to the issuance of new shares for the acquisition.
• **Employees (Akoya):** Akoya RSUs and Options will convert to Quanterix equivalents, maintaining their equity incentives under the new ownership structure.
• **Management (Akoya):** Current directors and executive officers are part of the 'Supporting Stockholders' group, indicating their support for the transaction. Quanterix will control Akoya's management post-merger.

Next Steps

• Quanterix will file a registration statement on Form S-4 with the SEC, which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix.
• Quanterix and Akoya may file other relevant documents regarding the merger with the SEC.
• A definitive copy of the joint proxy statement/prospectus will be mailed to Quanterix and Akoya stockholders when finalized.
• Akoya stockholders will vote on the adoption of the Merger Agreement.

Key Dates

Keywords

Merger, Acquisition, Quanterix Corporation, Akoya Biosciences Inc., SEC Filing, Schedule 13D, Common Stock, Exchange Ratio, Voting Agreement, Life Sciences, Diagnostics, Biotechnology